These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model. Yamamoto Y; Hyodo I; Takigahira M; Koga Y; Yasunaga M; Harada M; Hayashi T; Kato Y; Matsumura Y Int J Cancer; 2014 Jul; 135(1):214-23. PubMed ID: 24353132 [TBL] [Abstract][Full Text] [Related]
12. Speciation of oxaliplatin adducts with DNA nucleotides. Zayed A; Jones GD; Reid HJ; Shoeib T; Taylor SE; Thomas AL; Wood JP; Sharp BL Metallomics; 2011 Oct; 3(10):991-1000. PubMed ID: 21858382 [TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Rice JR; Gerberich JL; Nowotnik DP; Howell SB Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041 [TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750 [TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155 [TBL] [Abstract][Full Text] [Related]
16. Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles. Oberoi HS; Nukolova NV; Zhao Y; Cohen SM; Kabanov AV; Bronich TK Chemother Res Pract; 2012; 2012():905796. PubMed ID: 22844591 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Doroshow JH; Synold TW; Gandara D; Mani S; Remick SC; Mulkerin D; Hamilton A; Sharma S; Ramanathan RK; Lenz HJ; Graham M; Longmate J; Takimoto CH; Ivy P Semin Oncol; 2003 Aug; 30(4 Suppl 15):14-9. PubMed ID: 14523790 [TBL] [Abstract][Full Text] [Related]
18. Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. Mochida Y; Cabral H; Kataoka K Expert Opin Drug Deliv; 2017 Dec; 14(12):1423-1438. PubMed ID: 28290714 [TBL] [Abstract][Full Text] [Related]
19. Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin. Lila AS; Kiwada H; Ishida T Biol Pharm Bull; 2014; 37(2):206-11. PubMed ID: 24492717 [TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Culy CR; Clemett D; Wiseman LR Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]